July 2016 Issue Table Of Contents

From The Editor

• What Is At The Heart Of Biopharma Backlash?

Feature Articles

• Finding The Common Ground On Drug Pricing
• Will Kite Pharma Soar Higher In The Engineered T-Cell Race?

Capitol Perspectives

• Administration’s Response To Antibiotic Challenge Falls Far Short

Companies To Watch

• Tunitas Therapeutics

CEO Corner

• Biopharma Companies Are Focused On Access, Continued Innovation

Inside The Industry

• Why Animal Health Is The Next Big Growth Area
• Move Over ADCs: Nanoparticle-Drug Conjugates Are Joining The Cancer Fight
• Onboarding: Key To J&J’s Long-Term Investment Vision
• Leveraging China Innovation For Worldwide Growth
• The Changing Role Of The Pharma CIO
• How Do Patients View Your Investigational Medicinal Products?

Leadership Lessons

• 5 Fundamentals For Becoming An Exemplary Leader

Ask The Board

• There Are Rumors That The Contract Drug Substance (DS) And Drug Product (DP) Manufacturing Capabilities Past 2017 Are Fully Booked, Leaving The Pipelines Of BIO To Fend For Themselves. Any Validation To That?
• Do You Think The FDA Draft Guidance On Metrics Takes The Industry In The Right Direction?
• Do You Think The FDA Draft Guidance On Metrics Takes The Industry In The Right Direction?